We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By continuing to use our site, you accept our use of Cookies, Privacy Policy Term of use.
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
871 views • January 12, 2022

Government Control Led to Lack of COVID-19 Remedy: CEO

NTD News
NTD News
We look at a COVID-19 remedy called monoclonal antibodies—or MAB for short. They are basically antibodies made in a lab and they can potentially be life-saving. But this treatment is in short supply in many areas in the U.S. including but not limited to Connecticut, Nevada, and Ohio. NTD spoke with CEO Michael Einhorn who runs DealMed. He says there are a lot of reasons for the shortage of MABs, but he says government intervention is a main driver.
Show All
Comment 0